Results 21 to 30 of about 5,114,489 (264)

Investigation of Intravenous Zoledronic Acid Therapy on Circulating Lymphocyte Subpopulation in Patients with Primary Osteoporosis: A Pilot Study

Current Therapeutic Research, 2021
: Background: Several studies have investigated the immunomodulating properties of zoledronic acid on T lymphocytes, but the causal relationship between the function of T cells and the efficacy of zoledronic acid has not been elucidated Objective: To ...
Min Cui, Ph. D, Na Zhang, M.Med, Gang Zhang, B. Med, Lei Han, M.Med, Ling Zhi Yu, Ph. D   +4 more
doaj   +1 more source

Osteonecrosis of the Jaw Caused by Denosumab in Treatment-Naïve and Pre-Treatment with Zoledronic Acid Groups: A Time-to-Onset Study Using the Japanese Adverse Drug Event Report (JADER) Database

Drugs - Real World Outcomes, 2022
Background Medication-related osteonecrosis of the jaw is a serious adverse event associated with bone-modifying agents, such as injectable bisphosphonate (zoledronic acid) and the anti-receptor activator of nuclear factor-κB ligand antibody (denosumab).
S. Hasegawa, H. Ikesue, Riko Satake, Misaki Inoue, Yumiko Yoshida, Mizuki Tanaka, Kiyoka Matsumoto, W. Wakabayashi, K. Oura, Nobuyuki Muroi, T. Hashida, K. Iguchi, Mitsuhiro Nakamura   +12 more
semanticscholar   +1 more source

Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases

Supportive Care in Cancer, 2021
This study aimed to evaluate the association between clinical characteristics and development of medication-related osteonecrosis of the jaw (MRONJ) in patients who underwent dental examinations before the initiation of treatment with denosumab or ...
H. Ikesue, Moe Mouri, H. Tomita, M. Hirabatake, M. Ikemura, Nobuyuki Muroi, S. Yamamoto, T. Takenobu, K. Tomii, M. Kawakita, Hironori Katoh, T. Ishikawa, H. Yasui, T. Hashida   +13 more
semanticscholar   +1 more source

Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study.

Blood Advances, 2021
An exploratory end point from a recent trial in patients with newly diagnosed multiple myeloma showed that median progression-free survival (PFS) was increased by 10.7 months with denosumab vs zoledronic acid. We performed additional analyses to identify
E. Terpos, N. Raje, P. Croucher, R. García-Sanz, X. Leleu, W. Pasteiner, Yang Wang, A. Glennane, J. Canon, C. Pawlyn   +9 more
semanticscholar   +1 more source

Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials

Journal of Orthopaedic Surgery and Research, 2021
Objective To compare the efficacy and safety between denosumab and zoledronic acid for advanced cancer with bone metastasis. Methods MEDLINE, EMBASE, and the Cochrane library databases were searched for randomized controlled trials up to December 2020 ...
Lianghai Jiang, Xianghua Cui, Haoning Ma, Xiangsheng Tang   +3 more
semanticscholar   +1 more source

Reactive oxygen species and autophagy associated apoptosis and limitation of clonogenic survival induced by zoledronic acid in salivary adenoid cystic carcinoma cell line SACC-83. [PDF]

PLoS ONE, 2014
Salivary adenoid cystic carcinoma is an epithelial tumor in the head and neck region. Despite its slow growth, patients with salivary adenoid cystic carcinoma exhibit poor long term survival because of a high rate of distant metastasis. Lung and bone are
Xi-Yuan Ge, Lin-Qian Yang, Yang Jiang, Wen-Wen Yang, Jia Fu, Sheng-Lin Li   +5 more
doaj   +1 more source

Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases [PDF]

, 2015
PURPOSE: Bone metastases secondary to solid tumors increase the risk of skeletal-related events (SREs), including the occurrence of pathological fracture (PF), radiation to bone (RB), surgery to bone (SB), and spinal cord compression (SCC).
A Hussain, A Lipton, A Lipton, Ada Braun, Alison Stopeck, AM Abdulhalim, Arun Balakumaran, AT Stopeck, Blair Egerdie, C Nieder, Charles Cleeland, CS Cleeland, CS Cleeland, CS Cleeland, CS Cleeland, D Henry, Danail Damyanov, DF Cella, DH Henry, Donald L. Patrick, E Chow, F Saad, Felipe Salvador Palazzo, G Oster, Gavin Marx, GD Roodman, GR Mundy, GV Scagliotti, JA Ford, Janet Brown, Jean-Jacques Body, K Cetin, K Fizazi, K Fizazi, K Lemay, K Webster, KC Chung, L Costa, L Costa, L Costa, Lesley Fallowfield, LS Rosen, M Maltoni, M Norgaard, M Yong, MR Smith, N Sathiakumar, N Sathiakumar, R Moos von, R Moos von, RE Coleman, RE Coleman, Roger von Moos, S Vadhan-Raj, Yi Qian, Ying Zhou   +55 more
core   +5 more sources

Zoledronic Acid-Loaded Hybrid Hyaluronic Acid/Polyethylene Glycol/Nano-Hydroxyapatite Nanoparticle: Novel Fabrication and Safety Verification

Frontiers in Bioengineering and Biotechnology, 2021
Osteosarcoma is a malignant tumor that often occurs in adolescents and children. Zoledronic acid, a new-generation bisphosphonate, has been widely used as an antitumor drug to inhibit bone metastasis.
Yan Xu, Zheng Zhang, He-Hui Wang, Wu Zhong, Chengmei Sun, Wei Sun, Hongwei Wu   +6 more
semanticscholar   +1 more source

Evaluate the renal system damage caused by zoledronic acid: a comprehensive analysis of adverse events from FAERS. [PDF]

BMC Cancer
Wang Z, Su X, Shi D, Wei L.
europepmc   +3 more sources

Efficacy of Zoledronic Acid in Maintaining Areal and Volumetric Bone Density After Combined Denosumab and Teriparatide Administration: DATA‐HD Study Extension

Journal of Bone and Mineral Research, 2021
Combined teriparatide and denosumab rapidly and substantially increases bone mineral density (BMD) at all anatomic sites. Discontinuation of denosumab however, results in high‐turnover bone loss and increased fracture risk.
S. Ramchand, Natalie L David, Hang Lee, R. Eastell, J. Tsai, B. Leder   +5 more
semanticscholar   +1 more source